JAPAN ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST 2021-2025

The Japan Alzheimer’s disease therapeutics and diagnostics market is expected to project a CAGR of 5.82% during the forecast period, 2021-2025. The surging aging population is evaluated to be the crucial driver of market growth, along with the rising R&D activities. The base year considered for the study is 2020.

japan-alzheimers-disease-therapeutics-and-diagnostics-market

The World Aging 2019 report suggests that the population aged above 65 is set to reach 37.278 million in 2030, an increase of 30.9% from 2019. The elderly population is more susceptible to neurological disorders. Thus, with the growing geriatric population, the market is predicted to record considerable growth. Moreover, the country boasts of a sophisticated long-term care insurance system. It is universal and funded partly by insurance contributions, and by the tax. Further, Japan is adapting novel voluntary approaches to supplement the publicly funded healthcare provision. This is aiding the nation’s efforts to cope with diseases & disorders like Alzheimer’s disease. Such factors are projected to contribute to the market growth of Japan.

Eisai Co Ltd is a prominent global R&D-based pharmaceutical company. It is engaged in R&D, along with distribution, marketing, and manufacturing, and prioritizes prescription medicines. The company has 15 drug discovery, clinical research, and R&D sites. Neurology and Oncology are the key therapeutic areas of the company. It is headquartered in Bunkyo City, Tokyo, Japan.

TABLE OF CONTENTS
  1. RESEARCH SCOPE & METHODOLOGY
    1. STUDY OBJECTIVES
    2. SCOPE OF STUDY
    3. METHODOLOGY
    4. ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    1. MARKET SIZE & ESTIMATES
    2. COUNTRY SNAPSHOT
    3. COUNTRY ANALYSIS
    4. KEY GROWTH ENABLERS
    5. KEY CHALLENGES
  3. KEY ANALYTICS
    1. PORTER'S FIVE FORCES ANALYSIS
      1. THREAT OF NEW ENTRY
      2. THREAT OF SUBSTITUTION
      3. BUYER'S POWER
      4. SUPPLIER'S POWER
      5. COMPETITIVE RIVALRY
    2. IMPACT OF COVID-19 ON ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
    3. KEY BUYING CRITERIA
    4. ETYMOLOGY OF ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
    5. SUPPLY CHAIN ANALYSIS
    6. PHASES AND STERNNESS OF ALZHEIMER'S DISEASE
    7. OPPORTUNITY MATRIX
    8. VENDOR LANDSCAPE
    9. KEY INVESTMENT INSIGHTS
  4. MARKET BY THERAPEUTICS AND DIAGNOSTICS
    1. THERAPEUTICS
      1. THERAPEUTICS BY DRUGS
        1. MARKETED DRUGS
        2. PIPELINE DRUGS
      2. THERAPEUTICS BY DISEASE STAGE
        1. LATE STAGE: SEVERE AD
        2. EARLY/MIDDLE STAGE: MILD TO MODERATE AD
        3. PRODROMAL STAGE
      3. THERAPEUTICS BY GENERIC AND BRANDED
        1. BRANDED
        2. GENERIC
    2. DIAGNOSTICS
      1. LUMBAR PUNCTURE TEST
      2. POSITRON EMISSION TOMOGRAPHY
      3. ELECTROENCEPHALOGRAPHY
      4. MAGNETIC RESONANCE IMAGING
      5. COMPUTED TOMOGRAPHY
      6. OTHER DIAGNOSTICS
  5. COMPETITIVE LANDSCAPE
    1. KEY STRATEGIC DEVELOPMENTS
      1. MERGER & ACQUISITIONS
      2. PRODUCT LAUNCH & DEVELOPMENTS
      3. PARTNERSHIP, CONTRACT/AGREEMENT & COLLABORATION
      4. BUSINESS EXPANSION/ APPROVAL/ ANNOUNCEMENT
    2. COMPANY PROFILE
      1. EISAI CO LTD
      2. SUN PHARMACEUTICALS INDUSTRIES LTD
      3. LUPIN LIMITED
      4. BAXTER INTERNATIONAL INC
      5. ELI LILLY & COMPANY
      6. GE HEALTHCARE
      7. NOVARTIS AG
LIST OF TABLES

TABLE 1: MARKET SNAPSHOT - ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS

TABLE 2: JAPAN ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND DIAGNOSTICS, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 3: JAPAN ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND DIAGNOSTICS, FORECAST YEARS, 2021-2025 (IN $ MILLION)

TABLE 4: JAPAN THERAPEUTICS MARKET, BY DRUGS, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 5: JAPAN THERAPEUTICS MARKET, BY DRUGS, FORECAST YEARS, 2021-2025 (IN $ MILLION)

TABLE 6: JAPAN THERAPEUTICS MARKET, BY DISEASE STAGE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 7: JAPAN THERAPEUTICS MARKET, BY DISEASE STAGE, FORECAST YEARS, 2021-2025 (IN $ MILLION)

TABLE 8: JAPAN THERAPEUTICS MARKET, BY GENERIC AND BRANDED, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 9: JAPAN THERAPEUTICS MARKET, BY GENERIC AND BRANDED, FORECAST YEARS, 2021-2025 (IN $ MILLION)

TABLE 10: JAPAN DIAGNOSTICS MARKET, BY TYPE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 11: JAPAN DIAGNOSTICS MARKET, BY TYPE, FORECAST YEARS, 2021-2025 (IN $ MILLION)

LIST OF FIGURES

FIGURE 1: PORTER'S FIVE FORCE ANALYSIS

FIGURE 2: OPPORTUNITY MATRIX

FIGURE 3: VENDOR LANDSCAPE

FIGURE 4: KEY INVESTMENT INSIGHTS

FIGURE 5: JAPAN ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2021-2025 ($ MILLION)

FIGURE 6: JAPAN THERAPEUTICS MARKET, BY MARKETED DRUGS, 2021-2025 ($ MILLION)

FIGURE 7: JAPAN THERAPEUTICS MARKET, BY PIPELINE DRUGS, 2021-2025 ($ MILLION)

FIGURE 8: JAPAN THERAPEUTICS MARKET, BY LATE STAGE: SEVERE AD, 2021-2025 ($ MILLION)

FIGURE 9: JAPAN THERAPEUTICS MARKET, BY EARLY/MIDDLE STAGE: MILD TO MODERATE AD, 2021-2025 ($ MILLION)

FIGURE 10: JAPAN THERAPEUTICS MARKET, BY PRODROMAL STAGE, 2021-2025 ($ MILLION)

FIGURE 11: JAPAN THERAPEUTICS MARKET, BY BRANDED, 2021-2025 ($ MILLION)

FIGURE 12: JAPAN THERAPEUTICS MARKET, BY GENERIC, 2021-2025 ($ MILLION)

FIGURE 13: JAPAN ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2021-2025 ($ MILLION)

FIGURE 14: JAPAN DIAGNOSTICS MARKET, BY LUMBAR PUNCTURE TEST, 2021-2025 ($ MILLION)

FIGURE 15: JAPAN DIAGNOSTICS MARKET, BY POSITRON EMISSION TOMOGRAPHY, 2021-2025 ($ MILLION)

FIGURE 16: JAPAN DIAGNOSTICS MARKET, BY ELECTROENCEPHALOGRAPHY, 2021-2025 ($ MILLION)

FIGURE 17: JAPAN DIAGNOSTICS MARKET, BY MAGNETIC RESONANCE IMAGING, 2021-2025 ($ MILLION)

FIGURE 18: JAPAN DIAGNOSTICS MARKET, BY COMPUTED TOMOGRAPHY, 2021-2025 ($ MILLION)

FIGURE 19: JAPAN DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2021-2025 ($ MILLION)

Request For A Free Sample